Kyowa Hakko Kogyo Co., Ltd.

Millennium Pharmaceuticals Limited

Kyowa Hakko Kirin Co., Limited

Michio Ichimura

Yuji Nomoto

Kenji Matsuno

Shoji Oda

Shinichi Ide

Eiji Tsukuda

Robert M Scarborough

Anjali Pandey

Junko Sasaki

Fumio Suzuki

Shigeki Fujiwara

Junko Irie

Koji Yamada

Tetsuji Ohno

Hiroshi Kase

Junichi Shimada

Yoshisuke Nakasato

Etsuo Ohshima

Shunji Ichikawa

Kenji Ohmori

Haruki Takai

Hiromi Nonaka

Haruhiko Manabe

Daisuke Machii

Soichiro Sato

Yasuo Onoda

Takashi Kawakita

Hiroshi Tsumuki

Koji Yanagawa

Tohru Matsuzaki

Yoshihisa Kuwana

Shizuo Shiozaki

Susumu Iwamoto

Kyoichiro Iida

Hidee Ishii

Tomoyuki Kanda

Nobuo Kosaka

Iwao Kinoshita

Tomoko Ishikawa

Hideyuki Onodera

Ken Nagashima

Tsutomu Agatsuma

Setsuya Sasho

Rie Koike

Hironori Imma

Mayumi Saki

Shin-ichi Sasaki

Akiko Nakamura

Shin-ichi Ide

Makoto Suzuki

The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Quinazoline derivatives as kinase inhibitors

Nitrogenous heterocyclic compounds

The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomeruloscierosis.

The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which have inhibitory activity on the phosphorylation of kinases, which inhibits the activity of such kinases. The invention is also related to a method of inhibiting kinases and treating disease states in a mammal by inhibiting the phosphorylation of kinases. In a particular aspect the present invention provides nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salts thereof which inhibit phosphorylation of a of a PDGF receptor to hinder abnormal cell growth and cell wandering, and a method for preventing or treating cell-proliferative diseases such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Nitrogenous heterocylic compounds

Nitrogen-containing heterocyclic compounds

Derivatives of benzofuran or benzodioxazole compounds

Derivatives of benzofuran or benzodioxole

The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A,acceptor antagonising activity, and having an antiasthmatic action, a bronchodilator action, an antiantiitching action, etc., and represented by the following formula (I):

Condensed purine derivatives

&lsqb;1,2,4&rsqb;Triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A,receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A,receptors (for example, Parkinson's disease or senile dementia):

&lsqb;1,2,4&rsqb; triazolo &lsqb;1,5-C&rsqb; pyrimidine derivatives

1,3 diazines with platelet-derived growth factor receptor inhibitory activity

1,3 Diazines and pharmaceutically acceptable salts thereof inhibit phosphorylation of platelet-derived growth factor receptor and thereby hinder abnormal cell growth and cell wandering. The compounds may be used to treat or prevent cell-proliferative disorders such as arteriosclerosis, vascular reobstruction, cancer and glomerulosclerosis.

Growing community of inventors

Tokyo, Japan

Michio Ichimura